ALETA-004

N/A

Report date: 2024/11/22 15:03:14

Base Information

Drug NameALETA-004
Drug Alias NameALETA-004
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsAnti-C-Type lectin domain family 12 member AAnti-Myeloid cell surface antigen CD33
TargetsB-lymphocyte antigen CD19C-Type lectin domain family 12 member AMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAleta BioTherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAleta BioTherapeutics Inc
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A